Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The Mystery of IVIg

Eveline Wu, MD, Michael M. Frank, MD  |  Issue: March 2012  |  March 8, 2012

Other proposed mechanisms of action of IVIg include modulation of adhesion molecules expressed on various cell surfaces, suppression of cytokine expression, enhancement of regulatory T-cell function, and inhibition of dendritic cell maturation and function.1 High-dose IVIg may also upregulate expression of the inhibitory FcγRIIB, thereby exerting a negative feedback inhibition on antibody production.16 Thus, studies suggest that IVIg affects many steps in the immune response, and the critically important step may differ in various disease states.

Conclusion

Significant progress has been made in understanding the antiinflammatory effects of IVIg in the treatment of autoimmune and chronic inflammatory disorders. But, with the expansion of the number of clinical situations in which high doses of IVIg are effective, the risk of worldwide shortages of this agent also increases. A review of the literature highlights the need for more well-designed, controlled studies. Such studies are imperative to identify the clinical applications where IVIg is truly therapeutic. These studies will also provide more insight into the mechanisms of immune modulation. Further research is also needed to develop a molecularly engineered preparation of a recombinant IVIg to optimize its therapeutic efficacy and reduce the required dosage and thereby potential for shortage.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Disclosure

Dr. Frank is a consultant for CSL Behring. Dr. Wu is a fellow in the divisions of rheumatology and allergy/immunology, and Dr. Frank is the Samuel L. Katz Professor of Pediatrics, division of allergy/immunology, department of pediatrics, Duke University Medical Center, Durham, N.C.

References

  1. Ballow M. The IgG molecule as a biological immune response modifier: Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol. 2011;127:315-323.
  2. Berger M. A history of immune globulin therapy from the Harvard crash program to monoclonal antibodies. Curr Allergy Asthma Rep. 2002;2:368-378.
  3. Ballow M. Safety of IGIV therapy and infusion-related adverse events. Immunol Res. 2007;38:122-132.
  4. Gelfand EW. Differences between IGIV products: Impact on clinical outcome. Int Immunpharmacol. 2006;6:592-599.
  5. Imbach P, d’Apuzzo V, Hirt A, et al. High-dose intravenous immunoglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1:1228-1231.
  6. Nimmerjahn F, Ravetch JV. Antiinflammatory actions of intravenous immunoglobulin. Annu Rev Immunol. 2008;26:513-533.
  7. Fehr J, Hofmann V, Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous immunoglobulin. N Eng J Med. 1982;306:1254-1258.
  8. Sultan Y, Masionneuve P, Kazatchkine MD, et al. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet. 1984;2:765-768.
  9. Li N, Zhao M, Hilario-Vargas J, et al. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest. 2005;115:3440-3450.
  10. Basta M, Langlois PF, Marques M, et al. High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance. Blood. 1989;74:326-333.
  11. Basta M, Fries LF, Frank MM. High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood. 1991;77:376-380.
  12. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest. 1994;94:1729-1735.
  13. Dalakas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Eng J Med. 1993;329:1993-2000.
  14. Kaneko Y, Nimmerjahn F, Ravetch JV. Antiinflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 2006;313:670-673.
  15. Anthony RM, Wermeling F, Karlsson MC, et al. Identification of a receptor required for the antiinflammatory activity of IVIg. Proc Natl Acad Sci USA. 2008;105:19571-19578.
  16. Samuelsson A, Towers TL, Ravetch JV. Antiinflammatory activity of IVIg mediated through the inhibitory Fc receptor. Science. 2001;291:484-486.

Page: 1 2 3 4 5 6 7 8 | Single Page
Share: 

Filed under:ConditionsOther Rheumatic Conditions Tagged with:anti-inflammatorydrugHYDROXYCHLOROQUINEimmunodeficiencyinflammationintravenous immune globulinMethotrexatemyalgiapatient carePediatricsrheumatologistTreatment

Related Articles

    New Tools for Myositis Diagnosis, Classification & Management

    April 15, 2019

    CHICAGO—At Hot Topics in Myositis, a session at the 2018 ACR/ARHP Annual Meeting, three experts discussed new classification criteria for idiopathic inflammatory myopathies (IIM) and offered practical primers on overlap myositis conditions and inclusion body myositis (IBM). New Myositis Classification Criteria After a 10-year development process, the new EULAR/ACR Classification Criteria for Adult and Juvenile…

    MIA Studio / shutterstock.com

    Kawasaki Guideline Urges Treatment Intensification for Some Patients

    December 16, 2021

    A soon-to-be published guideline from the ACR and the Vasculitis Foundation on Kawasaki disease underscores the importance of early diagnosis and intensified treatment for people with this serious condition.1 Intravenous immunoglobulin (IVIG) remains the treatment mainstay, and prompt, aggressive treatment may be able to reduce the risk of serious complications in some patients. The guideline…

    Exploring Kawasaki Disease

    April 2, 2014

    New epidemiologic data, clinical studies have shed light on diagnosis, treatments, patient outcomes for this childhood disease, but etiology is still unknown

    Fellows’ Forum Case Report: Necrotizing Autoimmune Myopathy

    December 18, 2017

    Necrotizing autoimmune myopathy (NAM) is a relatively recently discovered subgroup of inflammatory myopathies. NAM is characterized by predominant muscle fiber necrosis and regeneration with little or no inflammation.1 One subgroup of NAM is 3-hydroxy-3-methylglutaryl-CoA reductase antibody (HMGCR Ab)-related immune-mediated necrotizing myopathy (IMNM), which occurs (rarely) after statin exposure, with a rough incidence of two per…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences